2022 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | Kelley, Robin Kate; Rimassa, Lorenza; ANN-LII CHENG ; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas | The Lancet. Oncology | 227 | 185 | |